Macitentan for the treatment of pulmonary arterial hypertension

References

• BenzaRLMillerDPBarstRJBadeschDBFrostAEMcGoonMDAn evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL RegistryChest2012142244845622281797
   PubMed Web of Science ®Google Scholar
• D’AlonzoGEBarstRJAyresSMSurvival in patients with primary pulmonary hypertension. Results from a national prospective registryAnn Intern Med199111553433491863023
   PubMed Web of Science ®Google Scholar
• YanagisawaMKuriharaHKimuraSA novel potent vasoconstrictor peptide produced by vascular endothelial cellsNature198833261634114152451132
   PubMed Web of Science ®Google Scholar
• RussellFDSkepperJNDavenportAPEvidence using immunoelectron microscopy for regulated and constitutive pathways in the transport and release of endothelinJ Cardiovasc Pharmacol19983134244309514188
   PubMed Web of Science ®Google Scholar
• RussellFDDavenportAPSecretory pathways in endothelin synthesisBr J Pharmacol1999126239139810077230
   PubMed Web of Science ®Google Scholar
• BoulangerCLuscherTFRelease of endothelin from the porcine aorta. Inhibition by endothelium-derived nitric oxideJ Clin Invest19908525875902153712
   PubMed Web of Science ®Google Scholar
• FirthJDRatcliffePJOrgan distribution of the three rat endothelin messenger RNAs and the effects of ischemia on renal gene expressionJ Clin Invest1992903102310311522210
   PubMed Web of Science ®Google Scholar
• TakahashiMMatsushitaYIijimaYTanzawaKPurification and characterization of endothelin-converting enzyme from rat lungJ Biol Chem19932682821394213988407980
   PubMed Web of Science ®Google Scholar
• LuscherTFBartonMEndothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugsCirculation2000102192434244011067800
   PubMed Web of Science ®Google Scholar
• PollockDMKeithTLHighsmithRFEndothelin receptors and calcium signalingFASEB J1995912119612047672512
   PubMed Web of Science ®Google Scholar
• HirataYEmoriTEguchiSEndothelin receptor subtype B mediates synthesis of nitric oxide by cultured bovine endothelial cellsJ Clin Invest1993914136713737682570
   PubMed Web of Science ®Google Scholar
• ShichiriMKatoHMarumoFHirataYEndothelin-1 as an autocrine/paracrine apoptosis survival factor for endothelial cellsHypertension1997305119812039369276
   PubMed Web of Science ®Google Scholar
• VerhaarMCStrachanFENewbyDEEndothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockadeCirculation19989787527569498538
   PubMed Web of Science ®Google Scholar
• OhuchiTKuwakiTLingGYElevation of blood pressure by genetic and pharmacological disruption of the ETB receptor in miceAm J Physiol19992764 Pt 2R1071R107710198387
   PubMedGoogle Scholar
• SauvageauSThorinECaronADupuisJEndothelin-1-induced pulmonary vasoreactivity is regulated by ET(A) and ET(B) receptor interactionsJ Vasc Res200744537538117495482
   PubMed Web of Science ®Google Scholar
• DupuisJHoeperMMEndothelin receptor antagonists in pulmonary arterial hypertensionEur Respir J200831240741518238950
   PubMed Web of Science ®Google Scholar
• TrowTKTaichmanDBEndothelin receptor blockade in the management of pulmonary arterial hypertension: selective and dual antagonismRespir Med2009103795196219304472
   PubMed Web of Science ®Google Scholar
• MacLeanMREndothelin-1: a mediator of pulmonary hypertension?Pulm Pharmacol Ther1998112–31251329918744
   PubMed Web of Science ®Google Scholar
• KirkbyNSHadokePWBagnallAJWebbDJThe endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house?Br J Pharmacol200815361105111917965745
   PubMed Web of Science ®Google Scholar
• ChannickRNSimonneauGSitbonOEffects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled studyLancet200135892881119112311597664
   PubMed Web of Science ®Google Scholar
• RubinLJBadeschDBBarstRJBosentan therapy for pulmonary arterial hypertensionN Engl J Med20023461289690311907289
   PubMed Web of Science ®Google Scholar
• BarstRJLanglebenDFrostASitaxsentan therapy for pulmonary arterial hypertensionAm J Respir Crit Care Med2004169444144714630619
   PubMed Web of Science ®Google Scholar
• GalieNBadeschDOudizRAmbrisentan therapy for pulmonary arterial hypertensionJ Am Coll Cardiol200546352953516053970
   PubMed Web of Science ®Google Scholar
• BarstRJRichSWidlitzAHornEMMcLaughlinVMcFarlinJClinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension: open-label pilot studyChest200212161860186812065350
   PubMed Web of Science ®Google Scholar
• DingemanseJSidhartaPNMaddreyWCRubinLJMickailHEfficacy, safety and clinical pharmacology of macitentan in comparison to other endothelin receptor antagonists in the treatment of pulmonary arterial hypertensionExpert Opin Drug Saf201413339140524261583
   PubMed Web of Science ®Google Scholar
• SidhartaPNvan GiersbergenPLHalabiADingemanseJMacitentan: entry-into-humans study with a new endothelin receptor antagonistEur J Clin Pharmacol2011671097798421541781
   PubMed Web of Science ®Google Scholar
• BrudererSHopfgartnerGSeiberlingMAbsorption, distribution, metabolism, and excretion of macitentan, a dual endothelin receptor antagonist, in humansXenobiotica201242990191022458347
   PubMed Web of Science ®Google Scholar
• IglarzMBinkertCMorrisonKPharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonistJ Pharmacol Exp Ther2008327373674518780830
   PubMed Web of Science ®Google Scholar
• AtsmonJDingemanseJShaikevichDVolokhovISidhartaPNInvestigation of the effects of ketoconazole on the pharmacokinetics of macitentan, a novel dual endothelin receptor antagonist, in healthy subjectsClin Pharmacokinet201352868569223568224
   PubMed Web of Science ®Google Scholar
• GatfieldJMueller GrandjeanCSasseTClozelMNaylerOSlow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cellsPLoS One2012710e4766223077657
   PubMed Web of Science ®Google Scholar
• HongISCoeHVCatanzaroLMMacitentan for the treatment of pulmonary arterial hypertensionAnn Pharmacother201448453854724458948
   PubMed Web of Science ®Google Scholar
• SidhartaPNLindeggerNUlcIDingemanseJPharmacokinetics of the novel dual endothelin receptor antagonist macitentan in subjects with hepatic or renal impairmentJ Clin Pharmacol Epub1032013
   PubMed Web of Science ®Google Scholar
• SidhartaPNvan GiersbergenPLDingemanseJSafety, tolerability, pharmacokinetics, and pharmacodynamics of macitentan, an endothelin receptor antagonist, in an ascending multiple-dose study in healthy subjectsJ Clin Pharmacol201353111131113823900878
   PubMed Web of Science ®Google Scholar
• SidhartaPNvan GiersbergenPLWoltzNDingemanseJInvestigation of mutual pharmacokinetic interactions between macitentan, a novel endothelin receptor antagonist, and sildenafil in healthy subjectsBr J Clin Pharmacol Epub6242014
   PubMed Web of Science ®Google Scholar
• BrudererSAänismaaPHomeryMCEffect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonistAAPS J2012141687822189899
   PubMed Web of Science ®Google Scholar
• SidhartaPNDietrichHDingemanseJInvestigation of the effect of macitentan on the pharmacokinetics and pharmacodynamics of warfarin in healthy male subjectsClin Drug Investig2014348545552
   PubMed Web of Science ®Google Scholar
• FattingerKFunkCPantzeMThe endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactionsClin Pharmacol Ther200169422323111309550
   PubMed Web of Science ®Google Scholar
• StiegerBFattingerKMadonJKullak-UblickGAMeierPJDrug-and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liverGastroenterology2000118242243010648470
   PubMed Web of Science ®Google Scholar
• SpiveyJRBronkSFGoresGJGlycochenodeoxycholate-induced lethal hepatocellular injury in rat hepatocytes. Role of ATP depletion and cytosolic free calciumJ Clin Invest199392117248325981
   PubMed Web of Science ®Google Scholar
• JansenPLStrautnieksSSJacqueminEHepatocanalicular bile salt export pump deficiency in patients with progressive familial intrahepatic cholestasisGastroenterology199911761370137910579978
   PubMed Web of Science ®Google Scholar
• KrumHViskoperRJLacourciereYBuddeMCharlonVThe effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension InvestigatorsN Engl J Med1998338127847909504938
   PubMed Web of Science ®Google Scholar
• ActelionOPsumit USers Registry (OPUS) Available from: NLM identifier: NCT02126943. http://clinicaltrials.gov/ct2/show/NCT02126943?term=macitentan&rank=13Accessed July 29, 2014
   Google Scholar
• ComellasAPBrivaADadaLAEndothelin-1 impairs alveolar epithelial function via endothelial ETB receptorAm J Respir Crit Care Med2009179211312218948426
   PubMed Web of Science ®Google Scholar
• IglarzMBossuAWannerDComparison of pharmacological activity of macitentan and bosentan in preclinical models of systemic and pulmonary hypertensionLife Sci Epub2262014
   PubMed Web of Science ®Google Scholar
• Center for Drug Evaluation and ResearchClinical Pharmacology and Biopharmaceutics Review, application number: 204410Orig1s0002013 Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204410Orig1s000ClinPharmR.pdfAccessed July 29, 2014
   Google Scholar
• PulidoTAdzerikhoIChannickRNMacitentan and morbidity and mortality in pulmonary arterial hypertensionN Engl J Med2013369980981823984728
   PubMed Web of Science ®Google Scholar
• GalieNSimonneauGBarstRJBadeschDRubinLClinical worsening in trials of pulmonary arterial hypertension: results and implicationsCurr Opin Pulm Med201016Suppl 1S11S1920375660
   PubMedGoogle Scholar
• HumbertMBarstRJRobbinsIMCombination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2Eur Respir J200424335335915358690
   PubMed Web of Science ®Google Scholar
• FöllerMMahmudHQadriSMEndothelin B receptor stimulation inhibits suicidal erythrocyte deathFASEB J20102493351335920427706
   PubMed Web of Science ®Google Scholar
• FonsecaCAbrahamDRenzoniEAEndothelin in pulmonary fibrosisAm J Respir Cell Mol Biol201144111020448055
   PubMed Web of Science ®Google Scholar
• KingTEJrBehrJBrownKKBUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosisAm J Respir Crit Care Med20081771758117901413
   PubMed Web of Science ®Google Scholar
• KingTEJrBrownKKRaghuGBUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosisAm J Respir Crit Care Med20111841929921474646
   PubMed Web of Science ®Google Scholar
• RaghuGBehrJBrownKKTreatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trialAnn Intern Med2013158964164923648946
   PubMed Web of Science ®Google Scholar
• CoralloCPecettiGIglarzMMacitentan slows down the dermal fibrotic process in systemic sclerosis: in vitro findingsJ Biol Regul Homeost Agents201327245546223830395
   PubMed Web of Science ®Google Scholar
• IglarzMLandskronerKReyMWannerDHessPClozelMOptimization of tissue targeting properties of macitentan, a new dual endothelin receptor antagonist, improves its efficacy in a rat model of pulmonary fibrosis associated with pulmonary arterial hypertensionAm J Respir Crit Care Med2011183A6445
   Web of Science ®Google Scholar
• RaghuGMillion-RousseauRMorgantiAPerchenetLBehrJGroupMSMacitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trialEur Respir J20134261622163223682110
   PubMed Web of Science ®Google Scholar
• GhofraniHAD’ArminiAMGrimmingerFRiociguat for the treatment of chronic thromboembolic pulmonary hypertensionN Engl J Med2013369431932923883377
   PubMed Web of Science ®Google Scholar
• BondermanDNowotnyRSkoro-SajerNBosentan therapy for inoperable chronic thromboembolic pulmonary hypertensionChest200512842599260316236930
   PubMed Web of Science ®Google Scholar
• HoeperMMKrammTWilkensHBosentan therapy for inoperable chronic thromboembolic pulmonary hypertensionChest200512842363236716236895
   PubMed Web of Science ®Google Scholar
• ActelionMERIT-1: macitentan in the treatment of inoperable chronic thromboembolic pulmonary hypertension Available from: http://clinicaltrials.gov/show/NCT02021292. NLM identifier: NCT02021292Accessed July 29, 2014
   Google Scholar